title: Safety and efficacy of biolimus-eluting stent with biodegradable polymer: insights from EINSTEIN (Evaluation of Next-generation drug-eluting STEnt IN patients with coronary artery disease) Registry.
abstract: OBJECTIVE
  To evaluate the incidence of major adverse cardiac events (cardiac death, or acute myocardial infarct, or target vessel revascularization) at one year in "real world" patients.
  
  
  METHODS
  The EINSTEIN registry is an observational, prospective, single center study that consecutively included 103 patients (152 lesions) treated with the BiomatrixTM stent, a biolimus A9-eluting stent with biodegradable polymer.
  
  
  RESULTS
  The mean age was 65.0±12.4 years; male gender represented 83.5% of the patients; and 37.9% of them were diabetic. At one-year, major adverse cardiac events occurred in 11.7% of the patients, including 2.9% of cardiac death, 4.9% of with non ST- segment elevation acute myocardial infarction, and 3.9% of target vessel revascularization. Stent thrombosis occurred in only 1% (1 patient) at one-yearfollow-up.
  
  
  CONCLUSIONS
  The present Registry suggests that new generation biolimus A9 drug-eluting stents are safe and effective in a "real world", all-comers patients, showing low rates of major cardiac adverse events on long-term follow-up.
authors.forename: Cristiano Freitas de
authors.initials: CF
authors.lastname: Souza
authors.forename: Anwar Mohamed
authors.initials: AM
authors.lastname: El Mouallem
authors.forename: Fábio Sândoli
authors.initials: FS
authors.lastname: de Brito Júnior
authors.forename: Alexandre Antônio Cunha
authors.initials: AA
authors.lastname: Abizaid
authors.forename: Breno Oliveira
authors.initials: BO
authors.lastname: Almeida
authors.forename: Amanda Gonçalves
authors.initials: AG
authors.lastname: Almeida
authors.forename: Teresa Cristina Dias Cunha
authors.initials: TC
authors.lastname: Nascimento
authors.forename: Marco Antonio
authors.initials: MA
authors.lastname: Perin
authors.forename: Adriano
authors.initials: A
authors.lastname: Caixeta
mesh_terms: D020341:Absorbable Implants / Q000009:adverse effects; D000368:Aged; D003324:Coronary Artery Disease / Q000601:surgery*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011108:Polymers / Q000008:administration & dosage*; D011446:Prospective Studies; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D011108:Polymers; C518022:umirolimus; D020123:Sirolimus